LOGIN  |  REGISTER
Amneal Pharmaceuticals

Latest Pharma and Biotech Patent News

FibroBiologics Files Patent Application Covering Fibroblast-based Technology for the Potential Treatment of Lupus

March 28
Last Trade: 10.81 0.00 0.00

HOUSTON, March 28, 2024 (GLOBE NEWSWIRE) -- FibroBiologics (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 150+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, announced the filing of a patent application with the United States Patent Office covering the use of FibroBiologics’ fibroblast...Read more


ReShape Lifesciences® Receives Notice of Allowance for Additional U.S. Patent Related to an Intragastric Balloon System

March 28
Last Trade: 0.18 0.0032 1.77

IRVINE, Calif., March 28, 2024 (GLOBE NEWSWIRE) -- ReShape Lifesciences® (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health-solutions company, today announced that the company has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for patent application 18/370,819, entitled, “Intragastric Device.” When issued, the patent will cover claims for an intragastric balloon system, comprising...Read more


Clearmind Medicine Announces International Patent Application for Preventing and Treating Depression

March 27
Last Trade: 1.15 -0.02 -1.71

Vancouver, Canada, March 27, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY) (“Clearmind” or the “company”), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, announced that it has submitted its tenth patent application under the international Patent Cooperation Treaty (“PCT”), as part of its ongoing collaboration with...Read more


Moleculin Biotech Announces U.S. Patent Issue Notification for Annamycin Targeting Unmet Need in AML

March 27
Last Trade: 5.91 0.37 6.68

Patent, once issued, will provide composition of matter protection through 2040, with potential for additional term extension Next-generation anthracycline uses unique lipid-based delivery technology to bring hope to the estimated 58% of AML patients for whom no approved therapy exists HOUSTON, March 27, 2024 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage...Read more


SciSparc-Clearmind Collaboration Evolves with New International Patent Application for Preventing and Treating Depression

March 27
Last Trade: 1.77 0.03 1.72

TEL AVIV, Israel, March 27, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced today that as part of its ongoing collaboration with Clearmind Medicine Inc. (“Clearmind”) (Nasdaq: CMND) (CSE: CMND) (FSE: CWY), a biotechnology company focused on...Read more


PharmAla Biotech: Patent Allowance Granted for ALA-002 Composition by US Patent and Trademark Office

March 27
Last Trade: 0.18 0.00 0.00

TORONTO, March 27, 2024 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of MDMA (MDXX class molecules), is extremely pleased to announce that the US Patent and Trademark Office (USPTO) has indicated it is issuing an allowance for the granting of a patent for ALA-002,...Read more


MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in Japan

March 26
Last Trade: 1.45 -0.02 -1.36

LA JOLLA, Calif., March 26, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced it has received a Notice of Allowance from the Japan Patent Office for a pending patent application which covers MN-166 (ibudilast) for the treatment of macular injury associated with progressive...Read more


Virios Therapeutics Announces Publication of International Patent for IMC-2 Covering Antiviral Treatment of Long-COVID

March 26
Last Trade: 0.48 -0.0046 -0.95

New patent would extend coverage and expand potential value of Virios’ antiviral pipeline globally Active Long-COVID characterized by immune dysfunction leading to recurrent herpesviruses reactivation Published data indicates increased Epstein-Barr herpes virus in Long-COVID patients, highlighting potential for antiviral therapy to treat fatigue and other Long-COVID symptoms ATLANTA, March 26, 2024 (GLOBE NEWSWIRE) -- Virios...Read more


Chemomab Therapeutics Awarded New European Patent for CM-101, Its First-in Class Monoclonal Antibody in Phase 2 Clinical Development for Primary Sclerosing Cholangitis

March 25
Last Trade: 0.78 0.009 1.17

European Patent Office Grants New Patent Covering Use of CM-101 for the Treatment of Multiple Liver Diseases including Primary Sclerosing Cholangitis Further Extends Protections Afforded by CM-101 Composition of Matter and Methods and Use Patents That Have Issued in the U.S., Europe, Israel and Related Territories TEL AVIV, Israel, March 25, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a...Read more


Myriad Genetics Announces Foundational Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date

March 21
Last Trade: 21.32 -0.08 -0.37

SALT LAKE CITY, March 21, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced that the United States Patent and Trademark Office has issued a patent that will strengthen its ability to deliver a tumor-informed, high-definition, molecular residual disease (MRD) assay to market.  U.S. patent 11,932,910, entitled Combinatorial DNA Screening, covers Myriad’s...Read more


Myriad Genetics Announces Patent Granted for SneakPeek® Snap Device

March 20
Last Trade: 21.32 -0.08 -0.37

SALT LAKE CITY, March 20, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced that the U.S. Patent and Trademark Office has granted a patent that covers the use of push-button blood collection devices for PCR-based fetal sex determination. U.S. Patent No. 11,932,907, titled Fetal Sex Determination Using Capillary Blood From Upper Arm, provides protection for...Read more


PharmAla Biotech: Patent Allowance Granted for P-1 Molecule by US Patent and Trademark Office

March 20
Last Trade: 0.18 0.00 0.00

TORONTO, March 20, 2024 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of MDMA (MDXX class molecules), is thrilled to announce that allowance has been granted for the Composition of Matter of its PharmAla-1 (P-1) molecule by the US Patent and Trademark Office...Read more


Lumos Pharma Announces that the USPTO Has Granted Patent Protection for Novel Formulation of LUM-201, Extending Exclusivity to 2042

March 20
Last Trade: 2.82 0.00 0.00

AUSTIN, Texas, March 20, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for Pediatric Growth Hormone Deficiency (PGHD) through Phase 2 clinical trials, announced that on Thursday, March 14, 2024, the Company received a Notice of Allowance from the US Patent and Trade Office (USPTO) for claims in its patent application number PCT/US22/050700 titled “Compactable...Read more


Immunic Receives Notice of Allowance for Composition-of-Matter Patent of a Specific Polymorph of Vidofludimus Calcium in the United States

March 20
Last Trade: 1.32 0.02 1.54

Patent Will Also Cover a Related Method of Production of the Material  Fourth U.S. Patent Directed to Use of Vidofludimus Calcium in Multiple Sclerosis  Multilayered Intellectual Property Strategy Provides Protection Into 2041 in the United States and Into 2039 Internationally, Unless Extended Further  NEW YORK, March 20, 2024 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a...Read more


Breakthrough in Wellness: Clearmind Medicine's Psychedelic Treatment Granted Divisional Patent Approval in China

March 19
Last Trade: 1.15 -0.02 -1.71

A Novel Approach to Combatting Binge Behaviors with Groundbreaking Psychedelic Therapy Tel Aviv, Israel / Vancouver, Canada, March 19, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY) (“Clearmind” or the "company"), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, announced that it has been granted divisional...Read more


SciSparc Granted Another Patent, Strengthening its Core Technology in Canada

March 18
Last Trade: 1.77 0.03 1.72

TEL AVIV, Israel, March 18, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, today announced that it has been granted a patent for its core-technology, the combination of cannabinoids and n-acylethanolamines, by the Canadian Intellectual Property...Read more


Silo Pharma Files Patent for Groundbreaking Ketamine Implant Therapeutic to Target Fibromyalgia and Chronic Pain

March 18
Last Trade: 1.95 0.04 2.09

Silo reports positive stability of SP-26 for time-release and dosage control SARASOTA, FL, March 18, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced that it has filed a provisional patent application titled...Read more


Galmed Pharmaceuticals Announces Grant of New Patent for the Combination of Aramchol with Resmetirom (MGL-3196, REZDIFFRA) for the Treatment of NASH and Liver Fibrosis

March 15
Last Trade: 0.35 0.02 4.88

TEL AVIV, Israel, March 15, 2024 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and fibrotic diseases announced today the grant of a European patent related to the use of a combination of Aramchol and Resmetirom (MGL-3196, REZDIFFRA) for the treatment of NASH/MASH and liver fibrosis. The patent was granted in France, Germany, Italy,...Read more


BioXcel Therapeutics Announces European Patent Office’s Grant of Patent for Method of Treating Agitation in Dementia Using Sublingual Dexmedetomidine

March 15
Last Trade: 2.82 -0.06 -2.08

NEW HAVEN, Conn., March 15, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology, today reported that the European Patent Office (EPO) granted the Company’s European Patent No. 3,562,486 (the “486 patent”) on March 13, 2024. The 486 patent covers the use of dexmedetomidine administered...Read more


Cyclo Therapeutics Announces Issuance of U.S. Patent Covering the Use of Trappsol® Cyclo™ for the Treatment of Alzheimer’s Disease

March 14
Last Trade: 1.39 -0.01 -0.71

GAINESVILLE, Fla. / Mar 14, 2024 / Business Wire / Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced the United States Patent and Trademark Office (USPTO) has granted U.S. Patent No. 11,925,659 titled, “Methods for Treating...Read more


GRI Bio Announces Notice of Allowance for Canadian Patent Covering Proprietary Natural Killer T (NKT) Cell Modulators

March 14
Last Trade: 0.76 -0.02 -2.56

Company advancing an innovative pipeline of NKT cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases Ongoing efforts to build a robust global patent estate for a growing pipeline targeting high-value indications in need of innovation  LA JOLLA, CA, March 14, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline...Read more


MedMira Receives Canadian Patent for its Unique Quantitative Diagnostic System

March 13
Last Trade: 0.09 0.00 0.00

HALIFAX, NS / ACCESSWIRE / March 13, 2024 / Today, MedMira Inc. (MedMira) (TSXV:MIR) announces the receipt of a Canadian patent patent (number 2,949,634) for its new innovative and quantitative test system. This is in addition to the U.S. patent (number 11,353,450) received in 2022. Through this new patent, MedMira is to further diversify its patent portfolio and expand on its Rapid Vertical Flow Technology® (RVF) based diagnostic tests....Read more


Genprex Receives Notice of Patent Grant for Korean Patent Claiming Reqorsa® Immunogene Therapy with PD-1 and PD-L1 Antibodies to Treat Cancers

March 12
Last Trade: 2.94 0.23 8.49

Expands on the previously granted patents covering the use of REQORSA in combination with immune checkpoint inhibitors applicable to Genprex's Acclaim-2 and Acclaim-3 clinical trials AUSTIN, Texas, March 12, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that...Read more


IceCure Medical Receives Notice of Patent Allowance in Japan for a Novel Cryogen Flow Control to Optimize Patient Outcomes

March 12
Last Trade: 1.20 0.01 0.84

Innovating as a global leader in cryoablation technologies, with 42 patents issued and allowed Cryogenic flow control enhances the efficacy and precision of cryoablation procedures CAESAREA, Israel, March 12, 2024 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure" or the "Company"), developer of the ProSense® System, a minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to...Read more


Immunovant Awarded U.S. Patent for IMVT-1402

March 12
Last Trade: 32.31 -0.21 -0.65

Composition of matter patent issued with coverage until June 2043 Patent also includes methods of use and methods of manufacturing claims NEW YORK, March 12, 2024 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced that the United States Patent and Trademark Office has issued U.S. Patent No. 11,926,669 (“the...Read more


Enveric Biosciences Announces New Patent Issuances Protecting Multiple Assets Covered by Non-Binding Term Sheets

March 12
Last Trade: 1.00 -0.02 -1.96

Patents extend compositional protection to proprietary compounds CAMBRIDGE, Mass. / Mar 12, 2024 / Business Wire / Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, today announced that, on March 5, 2024, the United States Patent and Trademark Office...Read more


RedHill Biopharma Announces New USPTO Patent Covering Talicia® Through 2034

March 11
Last Trade: 0.53 0.02 3.48

U.S. Patent and Trademark Office (USPTO) issues new patent covering Talicia1 as an all-in-one treatment of Helicobacter pylori (H. pylori), supporting Talicia protection until February 12, 2034 This new patent adds to the existing strong intellectual property portfolio protecting Talicia, including composition of matter and other patents and FDA-granted data exclusivities granted under the GAIN QIDP designation and section...Read more


ProMIS Neurosciences Strengthens Global Intellectual Property Portfolio

March 11
Last Trade: 1.91 0.16 9.14

CAMBRIDGE, Massachusetts and TORONTO, Ontario, March 11, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (Nasdaq: PMN), a biotechnology company focused on the generation and development of therapeutics targeting toxic misfolded proteins in neurodegenerative diseases, today announced that the European Patent Office, Japanese Patent Office and IP Australia, the Australian patent office, have recently allowed composition of matter...Read more


HeartBeam Receives Two New US Patents for its Core Cardiac Monitoring Technology

March 7
Last Trade: 2.18 -0.04 -1.80

Company Continues Expanding its Intellectual Property Footprint, Now has 14 US and 4 International Patents SANTA CLARA, Calif. / Mar 07, 2024 / Business Wire / HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through the power of personalized insights, announced today that it has received two new patents on its core vectorelectrocardiography (VECG) technology from the United States...Read more


SciSparc Granted Patent for Core Technology in Multiple Jurisdictions in Europe

March 7
Last Trade: 1.77 0.03 1.72

The Company's most recent patent further solidifies its position, complementing existing grants in the U.S., Japan, Australia and other key jurisdictions TEL AVIV, Israel, March 07, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced today...Read more


SciSparc Issued Canadian Patent for Opioids Reduction Use in Pain Management Technology

March 6
Last Trade: 1.77 0.03 1.72

TEL AVIV, Israel, March 06, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced today its had been received patent approval for its proprietary combination of opioids and n-acylethanolamines for pain treatment (the “Patent”). The Patent has...Read more


Phio Pharmaceuticals Announces Patent Granted by USPTO, Strengthening the Company’s Intellectual Property Position in Treating Aging Skin and Skin Disorders

March 6
Last Trade: 0.68 -0.05 -6.35

MARLBOROUGH, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, today announced that the United States Patent and Trademark Office (USPTO) has granted patent application 17/150,614 for two of its INTASYL Compounds, RXI-185 and RXI-231....Read more


HeartSciences Announces Canada Patent Grant Covering MyoVista® Wavelet Technology

March 6
Last Trade: 0.12 -0.0002 -0.17

Southlake, TX, March 06, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS; HSCSW) (“HeartSciences” or the “Company”), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced that the Canadian Intellectual Property Office Application No. 3,000,369 has been granted by the Canadian...Read more


Cardio Diagnostics Announces Issuance of Second U.S. Patent for Compositions and Methods for Detecting Predisposition to Cardiovascular Disease

March 5
Last Trade: 1.42 0.05 3.65

Company Continues to Build and Expand the Global IP Portfolio of Its One-of-a-Kind Technology CHICAGO / Mar 05, 2024 / Business Wire / Cardio Diagnostics Holdings, Inc. (NASDAQ: CDIO), an AI-driven precision cardiovascular medicine company, announces that the U.S. Patent and Trademark Office has issued a notice of allowance to University of Iowa Research Foundation ("UIRF") for U.S. Application No. 17,857,723 titled Compositions and...Read more


BioVaxys Technology Announces Allowance of DPX-Related Patent for Japan and Filing of Additional International Patent Applications

March 5
Last Trade: 0.07 -0.005 -6.67

VANCOUVER, BC, March 5, 2024 /CNW/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or "Company") announced that it has received a Notice of Allowance from the Japanese Patent Office for a Patent ("Patent") for inducing an antibody immune response from a low dose volume delivery of a B-cell epitope formulated with DPX™.  This Patent was part of the extensive Intellectual Property portfolio recently...Read more


BioLineRx Strengthens Intellectual Property Estate with Notice of Allowance for U.S. Patent Covering Method of Manufacturing Motixafortide (BL-8040) Suitable for Large Scale Production

March 4
Last Trade: 1.12 0.01 0.90

New patent, when issued, will be valid until December 2041 Additional IP complements U.S. market exclusivity awarded to BioLineRx upon FDA approval of APHEXDA® (motixafortide) in September 2023 as a result of its Orphan Drug and New Chemical Entity designations  TEL AVIV, Israel, March 4, 2024 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ/TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in...Read more


Defence Therapeutics Awarded Broad U.S. Patent Covering Its Pioneering Cancer-Killing AccuTOX(R) Technology

March 4
Last Trade: 1.71 0.01 0.59

Vancouver, British Columbia--(Newsfile Corp. - March 4, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing novel immune-oncology therapeutics and drug delivery technologies, is pleased to announce the granting of US patent no. 11,890,350 ('350) by the United States Patent and Trademark Office (USPTO), broadly covering its breakthrough...Read more


ASLAN Pharmaceuticals Receives Favorable Opinion From the European Patent Office on Composition of Matter Patent Application for Farudodstat

February 29
Last Trade: 0.62 -0.02 -2.50

New Composition of Matter Patent for farudodstat would strengthen intellectual property protection and provide commercial exclusivity for farudodstat until at least 2043 SAN MATEO, Calif. and SINGAPORE, Feb. 29, 2024 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals Ltd. (Nasdaq: ASLN), a clinical-stage, immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced it has...Read more


Adial Pharmaceuticals Awarded New Patent from the United States Patent and Trademark Office

February 28
Last Trade: 1.33 -0.07 -5.00

CHARLOTTESVILLE, Va., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced patent number 11,905,562 was issued on February 20, 2024 by the United States Patent and Trademark Office. The patent covers the Company’s lead...Read more


Can-Fite BioPharma Broadens its Strong Intellectual Property (IP) for NASH: Received Patent Allowance in Canada

February 28
Last Trade: 2.22 -0.04 -1.77

Patent has already been issued in other major markets including the U.S., EU, Japan and China PETACH TIKVA, Israel / Feb 28, 2024 / Business Wire / Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced it received a Notice of Allowance from the Canadian Intellectual Property Office...Read more


SciSparc-Clearmind Partnership Yields Three New International Patent Applications for MDMA, Ibogaine and Ketamine Compounds

February 27
Last Trade: 1.77 0.03 1.72

TEL AVIV, Israel, Feb. 27, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced today that as part of its ongoing collaboration with Clearmind Medicine Inc. (“Clearmind”) (Nasdaq: CMND) (CSE: CMND) (FSE: CWY), a biotechnology company focused on...Read more


TG Therapeutics Announces Issuance of Additional Patents for BRIUMVI® (ublituximab-xiiy)

February 27
Last Trade: 15.21 -0.36 -2.31

NEW YORK, Feb. 27, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) (TG) today announced the issuance of three additional patents by the United States Patent and Trademark Office (USPTO) for BRIUMVI® (ublituximab-xiiy), the first and only anti-CD20 monoclonal antibody approved in the US for patients with relapsing forms of multiple sclerosis (RMS) that can be administered in a one-hour infusion following the starting...Read more


Alpha Cognition Files U.S. Patent Application Covering an ALPHA-1062 Oral Formulation to Treat Mild to Moderate Alzheimer’s Disease

February 22
Last Trade: 0.80 0.02 2.56

VANCOUVER, British Columbia / Feb 22, 2024 / Business Wire / Alpha Cognition Inc. (CSE: ACOG) (OTCQB: ACOGF) (“Alpha Cognition” (ACI), or the “Company”), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, is pleased to announce that it has filed a new composition-of-matter patent that secures broad protection for its lead asset, ALPHA-1062, currently under review by the FDA for...Read more


Tenon Medical Announces Issuance of Notice of Allowance of Patent Application Which Further Enhances Important Claims for its Sacroiliac Joint Implant

February 22
Last Trade: 0.95 0.05 5.53

Received Notice of Allowance from the USPTO on February 15, 2024 LOS GATOS, CA / ACCESSWIRE / February 22, 2024 / Tenon Medical, Inc. ("Tenon" or the "Company") (NASDAQ:TNON), a company transforming care for patients suffering with certain sacroiliac joint disorders, today announced that on February 15, 2024, the United States Patent and Trademark Office ("USPTO") issued a Notice of Allowance for U.S. Patent Application Serial Number...Read more


RetinalGeniX Technologies Granted a Patent for System And Method For Visualization Of Ocular Anatomy

February 22
Last Trade: 3.50 0.00 0.00

PETALUMA, Calif., Feb. 22, 2024 (GLOBE NEWSWIRE) -- RetinalGeniX™ Technologies Inc. (OTCQB:RTGN) (“RetinalGeniX” or the “Company”) today announced that it has been granted a patent by the United States Patent and Trademark Office for the Company's System And Method For Visualization Of Ocular Anatomy. The present invention relates to systems and methods for visualizing eye anatomy for diagnostic and therapeutic purposes. It is an...Read more


Motus GI Granted a U.S. Patent for a Key Feature Embodied by the Pure-Vu® System to Avoid Clogging in Cleansing the GI Tract

February 21
Last Trade: 0.44 0.02 5.50

FORT LAUDERDALE, Fla., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc. (“the “Company”) (NASDAQ: MOTS), a medical technology company focused on improving endoscopic outcomes and experiences, today announced that the United States Patent and Trademark Office (USPTO) has issued the Company a new patent (patent # 11904085) titled, “Colon Cleaning System with Automatic Self-Purging Feature.” “We are pleased to announce further...Read more


TriLink BioTechnologies® Solidifies IP Position with Awarded Patents for CleanCap® Capping Technology in China and Canada

February 21
Last Trade: 8.67 0.09 1.05

TriLink’s CleanCap® Capping Technology is Patented Globally & TriLink is the Sole Authorized Manufacturer of CleanCap® Capping Analogs SAN DIEGO / Feb 21, 2024 / Business Wire / TriLink BioTechnologies (TriLink®), a Maravai LifeSciences company (NASDAQ: MRVI) and global provider of life science reagents and services, has been granted patents by the China National Intellectual Property Administration (CNIPA) and the Canadian...Read more


Eton Pharmaceuticals Awarded U.S. Patent for Proprietary Hydrocortisone Oral Liquid Formulation

February 21
Last Trade: 3.75 -0.05 -1.32

DEER PARK, Ill., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that the United States Patent and Trademark Office (“USPTO”) has granted the Company’s U.S. Patent Application No. 18/113,458, which covers the Company’s ET-400 product candidate’s proprietary...Read more


NurExone Biologic’s Intellectual Property Portfolio Expands

February 20
Last Trade: 0.77 0.01 1.32

TORONTO and HAIFA, Israel, Feb. 20, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (Germany: J90) (the “Company” or “NurExone”), a pioneering biopharmaceutical company, proudly underscores its expanding Intellectual Property (IP) portfolio, which will serve as the foundation for its strategic goal of licensing the innovative ExoTherapy platform to interested biotech companies. NurExone’s Intellectual property portfolio...Read more


Devonian Health Bolsters Intellectual Property With Issuance of U.S. Patent Covering a Method of Treatment of Inflammatory Bowel Disease

February 20
Last Trade: 0.22 0.005 2.38

QUÉBEC, Québec / Feb 20, 2024 / Business Wire / Devonian Health Group Inc. (“Devonian” or the “Company”) (TSXV: GSD; OTCQB: DVHGF), a clinical stage botanical pharmaceutical corporation focused on developing a unique portfolio of botanical pharmaceutical and cosmeceutical products, today announced that the United States Patent and Trademark Office (“USPTO”) has issued patent no. 11,723,938 B2 entitled, “Thylakoid Extract Composition and...Read more


ProPhase Labs Announces Significant Progress in BE-Smart Esophageal Cancer Test Development USPTO grants additional broad patents for BE-SMART

February 20
Last Trade: 6.47 0.21 3.35

Garden City, NY, Feb. 20, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a next generation biotech, genomics and diagnostics company, today announced important developments in the Company’s efforts to commercialize its novel BE-SMART esophageal cancer diagnostic test. BE-Smart is a novel diagnostic test that is intended to detect and quantify early signs of certain types of cancer in individuals...Read more


Clearmind Medicine Submits Three International Patent Applications for Next Generation Classic Psychedelic-Based Compounds

February 20
Last Trade: 1.15 -0.02 -1.71

Vancouver, Canada, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” or the "company"), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, announced today that it has submitted three patent applications under the international Patent Cooperation Treaty ("PCT"), as part of its ongoing...Read more


Chemomab Therapeutics Awarded New Patents for CM-101, Its First-in Class Monoclonal Antibody in Clinical Development for Fibro-Inflammatory Diseases

February 20
Last Trade: 0.78 0.009 1.17

CM-101 Phase 2 Trial for the Treatment of Primary Sclerosing Cholangitis (PSC) Has Completed Patient Enrollment with Topline Data Expected Midyear 2024 New CM-101 Patents Granted by Brazil and Israel Provide Additional Protections for Composition of Matter and for Use in Fibrotic Diseases of the Liver, including PSC Further Extend Protections Afforded by Multiple CM-101 Patents that Have Issued in the U.S., Europe, Israel and...Read more


ENDRA Life Sciences Bolsters TAEUS® System Intellectual Property with New Patents in U.S., China and Europe

February 14
Last Trade: 0.58 -0.24 -29.29

Global Intellectual Property Portfolio Expands to 74 Issued Patents ANN ARBOR, Mich. / Feb 14, 2024 / Business Wire / ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), announces the issuance of three new patents, including one in the U.S., one in China and one in Europe. ENDRA’s intellectual property portfolio now includes 74 issued patents worldwide providing protection for the TAEUS...Read more


Inspira Technologies Receives First Ever U.S. Patent Approval for an Orbiting Blood Oxygenation Delivery System

February 14
Last Trade: 1.75 -0.01 -0.57

94% of the Claims Were Found to be Novel RA'ANANA, Israel, Feb. 14, 2024 /PRNewswire/ -- Inspira™ Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) (Nasdaq: IINNW) (the "Company" or "Inspira Technologies"), is a breakthrough medical technology company targeting to supersede mechanical ventilators, has received the first ever U.S. Patent approval for an orbiting blood oxygenation delivery system, a core technology of the...Read more


Calliditas Therapeutics provides patent update

February 13
Last Trade: 21.49 0.00 0.00

STOCKHOLM, Feb. 13, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Calliditas") today announced that the United States Patent and Trademark Office (USPTO) issued patent no. 11896719, entitled "New Pharmaceutical Compositions, on January 24, 2024 with validity as of today, February 13, 2024.  This is Calliditas' second patent for TARPEYO in the United States, and provides product protection...Read more


Adial Pharmaceuticals Awarded New Patent Notice of Allowance from the United States Patent and Trademark Office

February 13
Last Trade: 1.33 -0.07 -5.00

CHARLOTTESVILLE, Va., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced it has been awarded an important patent which expands the estate covering the combination of the Company’s proprietary genetic diagnostic to...Read more


GeoVax Labs Announces Multiple Patent Issuances and Allowances

February 13
Last Trade: 2.00 0.15 8.11

Intellectual Property Assets Strengthened for Cancer Immunotherapy Program and for Marburg Virus and HIV Vaccines ATLANTA, GA, Feb. 13, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced multiple actions by global patent offices strengthening the Company’s intellectual property...Read more


Coya Therapeutics Licenses Intellectual Property Rights for Use of Next Generation Immune Modulatory Biologics in Combination with COYA 301 to Enhance Regulatory T Cells (Tregs) in Inflammatory Diseases

February 13
Last Trade: 9.92 0.27 2.80

License from University of Nebraska Medical Center covers multiple low dose interleukin-2 (ld IL-2) combinations, including ld IL-2 + Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF); New data, viewable here, illustrate that the combination of ld IL-2 + GM-CSF results in a 4-6 fold synergistic increase in Tregs; License expands on Coya’s multi-pathway approach in identifying and combining immunomodulatory drugs with COYA 301...Read more


ABVC BioPharma Receives Australian Patent, Valid Until 2040, for Its Treatment of Major Depressive Disorder (MDD)

February 12
Last Trade: 1.31 0.11 9.17

The Company holds a U.S. patent for the same treatment FREMONT, CA , Feb. 12, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, neurology, and oncology/hematology, announced today that it received an Australian patent, valid until 2040, Application No. 2021314052, for the use of...Read more


Sensus Healthcare Issued U.S. Patent for SRT-100 Vision® System (IG-SRT) Capabilities

February 8
Last Trade: 3.80 -0.12 -3.06

BOCA RATON, Fla., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces that the U.S. Patent and Trademark Office (USPTO) has issued Patent No. 11,894,123 B2, titled “Radiotherapy Mobile and Wireless Device Workflow Management...Read more


Quoin Pharmaceuticals Files U.S. and International Patent Applications for Novel Netherton Syndrome Combination Product

February 8
Last Trade: 0.95 0.08 9.20

ASHBURN, Va., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a specialty pharmaceutical company exclusively focused on the development and commercialization of innovative therapies that treat rare and orphan diseases, today announced it has filed U.S. and International patent applications for a novel combination product as a potential treatment of Netherton Syndrome. This new...Read more


Mydecine Innovations Receives Two Notice of Allowances from USPTO for its MYCO-005 and MYCO-006 Family of Compounds

February 7
Last Trade: 0.0093 -0.0051 -35.42

VANCOUVER, British Columbia, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (CSE:MYCO) (AQSE:MYIG) (OTC:MYCOF) (FSE:0NF0), a leading biotechnology company dedicated to transforming mental health and addiction treatment, proudly announces the issuance of two Notice of Allowances by the United States Patent and Trademark Office (USPTO) for compounds from the Company’s MYCO-005 and MYCO-006...Read more


Biodexa Pharmaceuticals Announces Allowance of U.S. Patent Covering Tolimidone

February 7
Last Trade: 1.62 0.76 88.59

Biodexa plans to initiate a Phase 2 clinical program of tolimidone in Type 1 diabetes, following several preclinical studies demonstrating its role in beta cell survival Safety profile established in prior human studies of more than 700 patients CARDIFF, United Kingdom, February 7, 2024 (GLOBE NEWSWIRE) -- Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”)(Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a...Read more


Enlivex Therapeutics Announces Issuance of New U.S. Patent Covering Allocetra Cells and Their Manufacturing Method

February 7
Last Trade: 3.79 -0.07 -1.81

Nes-Ziona, Israel, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd., (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that the U.S. Patent and Trademark Office issued a new patent, number US 11,883,429, covering AllocetraTM, the Company’s immunotherapy product candidate. The new patent is expected to provide added intellectual property protection in the United...Read more


Cybin Announces Grant of Two Additional Patents in Japan in Support of its DMT Program

February 7
Last Trade: 0.41 -0.02 -3.84

Newly issued patents include protection for injectable formulations and synthesis methods for the preparation of dimethyltryptamine (“DMT”) and deuterated DMT (“dDMT”)  Patent protection further strengthens intellectual property portfolio in the 3rd largest pharmaceutical market globally  Cybin’s patent portfolio now includes 51 granted patents and over 170 pending applications  TORONTO / Feb 07, 2024 / Business Wire /...Read more


Tenax Therapeutics Announces USPTO Grants Notice of Allowance for U.S. Patent Application, Significantly Broadening IP Protection for Use of Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

February 6
Last Trade: 4.24 0.37 9.56

Once granted, this patent will: provide U.S. intellectual property (IP) protection until December 2040, and may qualify for additional U.S. patent term extension (PTE) beyond 2040 broaden IP protection for oral (TNX-103), IV, and subcutaneous use of levosimendan, and its active metabolites (OR1896 and OR1855), in PH-HFpEF expressly provide IP protection for levosimendan at all therapeutic doses for use in PH-HFpEF expressly provide...Read more


Iridex Receives European Patent on MicroPulse Technology

February 6
Last Trade: 2.98 0.03 1.02

MOUNTAIN VIEW, Calif., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced the grant of the European Patent EP 3009093, entitled "Laser System with Short Pulse Characteristics and its Methods of Use”. This groundbreaking patent further...Read more


electroCore Expands Intellectual Property Portfolio

February 6
Last Trade: 6.17 0.30 5.11

ROCKAWAY, N.J., Feb. 06, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the United States Patent and Trademark Office has issued a patent related to systems and methods for treating disorders associated with viruses in the Coronaviridae family (COVID). U.S. Patent No. 11,894,148 entitled “Systems and Methods for Treating Patients With Diseases...Read more


Clearmind Medicine Receives Patent Approval for its Psychedelic Based Treatment of Binge Behaviors in China

February 5
Last Trade: 1.15 -0.02 -1.71

Tel Aviv, Israel / Vancouver, Canada, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” or the "company"), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, announced today that it has been granted divisional patent approval by the China National Intellectual Property Administration. The...Read more


Aurora Spine’s Second Patent Related to DEXA Technology™ Patient-Matched Implant Technology Issued by the United States Patent Office

February 5
Last Trade: 0.40 0.06 16.18

CARLSBAD, Calif., Feb. 05, 2024 (GLOBE NEWSWIRE) -- Aurora Spine Corporation (“Aurora Spine” or the “Company”) (TSXV: ASG), a designer and manufacturer of innovative medical devices that improve spinal surgery outcomes, today announced the issuance of its second United States Patent No: 11,850,162 entitled “Body Density Scan Result-Matched Orthopedic Implants and Methods of Use” for The World’s First DEXA Technology™ Patient-Matched...Read more


BioXcel Therapeutics Announces USPTO’s Allowance of Patent Application for Method of Treating Agitation in Alzheimer’s Disease Using Oromucosal Formulations of Dexmedetomidine

February 5
Last Trade: 2.82 -0.06 -2.08

Aligns with Company’s strategic focus on bringing to market BXCL501 for potential acute treatment of agitation for Alzheimer’s patients  IGALMI™ market exclusivity further strengthened with receipt of issue notification for additional method of use patent (total of 8 U.S. patents, including 4 method of use patents)  NEW HAVEN, Conn., Feb. 05, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a...Read more


SeaStar Medical Granted Canadian Patent with Broad Claims Covering the Selective Cytopheretic Device Technology

February 1
Last Trade: 0.73 0.03 3.67

DENVER, Feb. 01, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, announces the issuance by the Canadian Intellectual Property Office of Canadian Patent No. 2814586. This new patent has broad claims covering the Company’s Selective Cytopheretic Device (SCD) technology. Its issuance expands...Read more


Kane Biotech Files New Patent on revyve™ Antimicrobial Wound Gel Spray

January 31
Last Trade: 0.10 0.00 0.00

WINNIPEG, Manitoba, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) (the “Company” or “Kane Biotech” or “Kane”) announces that it has filed a patent on its revyve™ Antimicrobial Wound Gel Spray, a follow-on product to its FDA 510(k) cleared revyve™ Antimicrobial Wound Gel, and will be introducing it today at the Boswick Burn and Wound Care Symposium. “Kane has taken their revyve™ Antimicrobial Wound Gel and...Read more


Algernon Pharmaceuticals Receives Notice of Intention to Grant from Chinese Patent Office for Repirinast to Treat CKD

January 31
Last Trade: 0.11 -0.01 -8.33

VANCOUVER, British Columbia, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) a Canadian clinical stage pharmaceutical development company, is pleased to announce that it has received a notice of intention to grant from the Chinese Patent Office for patent application No. 201980043698.6 for its antifibrotic drug candidate NP-251...Read more


Cyclo Therapeutics Announces Allowance of Patent Application for Treatment of Alzheimer’s Disease from the U.S. Patent and Trademark Office

January 29
Last Trade: 1.39 -0.01 -0.71

GAINESVILLE, Fla. / Jan 29, 2024 / Business Wire / Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced that the Company received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) regarding Cyclo...Read more


Longeveron Receives Notice of United States Patent Allowance for the Technology Behind its Lead Investigation Product Lomecel-B™

January 29
Last Trade: 3.25 0.14 4.50

MIAMI, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions , today announces it received a notice of patent allowance from the United States Patent and Trademark Office (PTO) for Medicinal Signaling Cells (MSCs), the technology behind its lead investigational product...Read more


The United States Patent Office Grants New Patent for Aurora Spine’s Translucent GhostTube™ Surgical Operating Tube

January 29
Last Trade: 0.40 0.06 16.18

CARLSBAD, Calif., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Aurora Spine Corporation (“Aurora Spine” or the “Company”) (TSXV: ASG), a designer and manufacturer of innovative medical devices that improve spinal surgery outcomes, today announced the issuance of its United States Patent No: 11,832,853 entitled “Hybrid Radiolucent Surgical Operating Tube”. Aurora Spine’s Ghost Tube™ was designed to provide superior anchoring with a translucent...Read more


Malaysian Patent Granted for CytoMed Therapeutics' Licensed Allogeneic CAR-Gamma Delta T Cell Technology

January 29
Last Trade: 2.17 -0.07 -3.12

SINGAPORE, Jan. 29, 2024 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based biopharmaceutical company focused on harnessing its proprietary technologies to develop novel donor-derived cell-based immunotherapies for the treatment of various cancers, announced today that the Intellectual Property Corporation of Malaysia has granted a patent for its chimeric antigen receptor gamma...Read more


Vanda Pharmaceuticals Announces a U.S. Patent Allowance for PONVORY® (ponesimod) in the U.S.

January 25
Last Trade: 4.11 0.22 5.66

WASHINGTON, Jan. 25, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the U.S. Patent and Trademark Office has issued a notice of allowance for its PONVORY® (ponesimod) patent application, number 17/962,968, covering methods for reducing clinical management events before or during the treatment of multiple sclerosis and methods for reinitiating treatment after missed doses. When issued, this...Read more


RedHill Biopharma Announces New USPTO Patent Grant for Talicia® for H. pylori Treatment Through 2042

January 25
Last Trade: 0.53 0.02 3.48

USPTO issues new patent covering Talicia[1] as a method for eradicating H. pylori regardless of patient Body Mass Index (BMI)[2], supporting Talicia protection until May 2042 The patent is supported by previously published pooled data from two Phase 3 studies showing Talicia's efficacy was unaffected by presence of elevated BMI[3] The U.S. FDA recently granted five years' market exclusivity for Talicia under the Generating Antibiotic...Read more


Altamira Therapeutics Files Second Provisional Patent Application for OligoPhore Nanoparticles Targeting Different KRAS Mutations in Cancer Treatment

January 24
Last Trade: 2.07 -0.28 -11.91

Altamira’s polyKRASmut siRNA shown to knock down at least 65-91% of KRAS mutations in colorectal, non-small cell lung, and pancreatic cancer cell lines Fresh experimental data expected to strengthen Altamira’s intellectual property around its AM-401 nanoparticles for the treatment of KRAS-driven cancers HAMILTON, BERMUDA, Jan. 24, 2024 -- Altamira Therapeutics Ltd. (Nasdaq: CYTO) ("Altamira" or the "Company"), a company...Read more


Modular Medical Announces Issuance of New US Patent

January 24
Last Trade: 1.85 -0.10 -5.13

SAN DIEGO, CA / ACCESSWIRE / January 24, 2024 / Modular Medical, Inc. (NASDAQ:MODD) ("Modular Medical" or the "Company"), a development-stage, insulin delivery technology company seeking to launch the next generation of user-friendly and affordable insulin pump technology, today announced the issuance of U.S. Patent 11,817,197 B2 for the stream-lined pairing of a pump to a mobile device. Paul DiPerna, Chairman and CTO of Modular Medical,...Read more


MAIA Biotechnology Announces Publication of International PCT Patent Application Covering Anticancer Telomere-Targeting Compounds

January 24
Last Trade: 2.20 -0.28 -11.29

New patent would extend coverage and expand potential value of MAIA’s telomere-targeting platform globally CHICAGO / Jan 24, 2024 / Business Wire / MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that the World Intellectual Property Organization (WIPO) has published MAIA’s global Patent Cooperation Treaty...Read more


Nexalin Technology Awarded Key Patent Related to its Non-Invasive, Frequency-Based Deep-Brain Stimulation Device – the Transcranial Alternating Current Dynamic Frequency Stimulation (TACS) System

January 23
Last Trade: 1.40 0.62 79.49

HOUSTON, TX, Jan. 23, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) today announced that the United States Patent and Trademark Office (USPTO) has awarded U.S. Patent No. 11,872,397 relating to the Company’s non-invasive, frequency-based deep brain stimulation device.  The newly-issued patent, entitled “Transcranial Alternating Current Dynamic Frequency Stimulation (TACS) System,”...Read more


bioAffinity Technologies Announces Award of Therapeutic Patent for Treatment of Cancer

January 23
Last Trade: 2.02 -0.06 -2.88

Indian Patent Office Grants Patent Related to Porphyrin Compounds for Targeted Cancer Treatment SAN ANTONIO / Jan 23, 2024 / Business Wire / bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage cancer and lung disease, today announced that India’s Office of the Controller General of Patents, Designs and Trade Marks has issued a...Read more


PetVivo Recieves Notice of Allowance from United States Patent and Trademark Office for Key Patent Application

January 23
Last Trade: 1.07 0.00 0.00

MINNEAPOLIS, MN, Jan. 23, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) (the "Company") an emerging biomedical device company focused on the commercialization of innovative medical devices and therapeutics for companion animals is pleased to announce that the United States Patent and Trademark Office (USPTO) has issued a notice of allowance for a patent application related to the Company’s proprietary...Read more


Anixa Biosciences Announces Japanese Patent on Ovarian Cancer Vaccine Technology

January 23
Last Trade: 3.12 -0.11 -3.41

Broad coverage extended to Japan and related regions SAN JOSE, Calif., Jan. 23, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a clinical-stage biotechnology company focused on the treatment and prevention of cancer, today announced that its collaborator, Cleveland Clinic, has received a "Decision to Grant" notice from the Japan Patent Office (JPO) for the patent...Read more


Envoy Medical Announces Three Additional Patents for Implantable Cochlear Systems

January 22
Last Trade: 3.92 0.01 0.26

Expanding Innovation Portfolio to Support Delivering Hearing to Patients in Innovative Ways WHITE BEAR LAKE, Minnesota, Jan. 22, 2024 (GLOBE NEWSWIRE) -- Envoy Medical®, Inc. (“Envoy Medical”) (NASDAQ: “COCH”), a revolutionary hearing health company focused on fully implanted hearing systems, today announced that it recently has been awarded three additional patents. These patents are further evidence of Envoy Medical’s...Read more


GH Research Announces Grant of European Patent Covering all Mebufotenin (5-MeO-DMT) and Mebufotenin Salt Products For Use in the Treatment of Major Depressive Disorder and Treatment-Resistant Depression

January 18
Last Trade: 10.66 -0.05 -0.47

DUBLIN, Ireland, Jan. 18, 2024 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today announced that it recently received a communication from the European Patent Office (EPO) that it has been granted a patent with claims directed to mebufotenin (5-MeO-DMT) or a pharmaceutically acceptable salt thereof for...Read more


Sign Up To Get Daily Life Science Stock News

Please review our Disclaimer and Privacy Policy before subscribing.

Featured Stock

ClearPoint Neuro

ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...

CLICK TO LEARN MORE

COPYRIGHT ©2023 HEALTH STOCKS HUB